Abstract:In recent years, multidrug-resistant pathogenic microorganisms (MDROs) have emerged as a severe threat to human health, exhibiting robust resistance to traditional antibiotics. This has created a formidable challenge in modern medicine as we grapple with limited options to combat these resilient bacteria. Despite extensive efforts by scientists to develop new antibiotics targeting these pathogens, the quest for novel antibacterial molecules has become increasingly arduous. Fortunately, nature offers a potential solution in the form of cationic antimicrobial peptides (AMPs) and their synthetic counterparts. AMPs, naturally occurring peptides, have displayed promising efficacy in fighting bacterial infections by disrupting bacterial cell membranes, hindering their survival and reproduction. These peptides, along with their synthetic mimics, present an exciting alternative in combating antibiotic resistance. They hold the potential to emerge as a formidable tool against MDROs, offering hope for improved strategies to protect communities. Extensive research has explored the diversity, history, and structure-properties relationship of AMPs, investigating their amphiphilic nature for membrane disruption and mechanisms of action. However, despite their therapeutic promise, AMPs face several documented limitations. Among these challenges, poor pharmacokinetic properties stand out, impeding the attainment of therapeutic levels in the body. Additionally, some AMPs exhibit toxicity and susceptibility to protease cleavage, leading to a short half-life and reduced efficacy in animal models. These limitations pose obstacles in developing effective treatments based on AMPs. Furthermore, the high manufacturing costs associated with AMPs could significantly hinder their widespread use. In this review, we aim to present experimental and theoretical insights into different AMPs, focusing specifically on antibacterial peptides (ABPs). Our goal is to offer a concise overview of peptide-based drug candidates, drawing from a wide array of literature and peer-reviewed studies. We also explore recent advancements in AMP development and discuss the challenges researchers face in moving these molecules towards clinical trials. Our main objective is to offer a comprehensive overview of current AMP and ABP research to guide the development of more precise and effective therapies for bacterial infections.

Mining and Biosynthesis of Bioactive Lanthipeptides from Microorganisms.

Mining public genomic databases for novel lanthipeptides: a case study on Bacillus amyloliquefaciens

Rule-based omics mining reveals antimicrobial macrocyclic peptides against drug-resistant clinical isolates

Engineering ribosomally synthesized and posttranslationally modified peptides as new antibiotics

Microbial-derived peptides with anti-mycobacterial potential

Challenges and advances in genome mining of ribosomally synthesized and post-translationally modified peptides (RiPPs)

Antimicrobial Peptides: Recent Insights on Biotechnological Interventions and Future Perspectives

Antimicrobial Peptides: The Production of Novel Peptide-Based Therapeutics in Plant Systems

Advancements, challenges and future perspectives on peptide-based drugs: Focus on antimicrobial peptides

Advances in microbial antimicrobial peptides expression system and transformation strategy

Antimicrobial Peptides as Effective Agents Against Drug-Resistant Pathogens

Using chemical synthesis to optimise antimicrobial peptides in the fight against antimicrobial resistance

Mining the bacterial genome to discover new antimicrobial molecules

Mining of the biosynthetic potential of archaea reveals diverse anti-archaeal lanthipeptides

Recent Advances in Polypeptide Antibiotics Derived from Marine Microorganisms

A Scalable Platform to Discover Antimicrobials of Ribosomal Origin

Antimicrobial Peptides: A Promising Therapeutic Strategy in Tackling Antimicrobial Resistance

A New Era of Antibiotics: The Clinical Potential of Antimicrobial Peptides

Antimicrobial Peptides in the Global Microbiome: Biosynthetic Genes and Resistance Determinants

Advancements in peptide-based antimicrobials: A possible option for emerging drug-resistant infections

Analysis of modular bioengineered antimicrobial lanthipeptides at nanoliter scale